Technical Analysis for RIGL - Rigel Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 1.34 | -1.47% | -0.02 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -1.47% |
Alert | Time |
---|---|
Possible NR7 | about 17 hours ago |
Possible Inside Day | about 17 hours ago |
Fell Below 50 DMA | about 21 hours ago |
50 DMA Support | about 21 hours ago |
Down 3% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 04/30/2024
Rigel Pharmaceuticals, Inc. Description
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase I clinical trials to treat keratoconjunctivitis sicca. The company also conducts preclinical studies for an oral activator of adenosine monophosphate activated protein kinase to enhance the body's energy utilization and restore muscle endurance in chronically ill subjects. Rigel Pharmaceuticals, Inc. has collaboration agreements with AstraZeneca AB to develop and commercialize oral SYK inhibitors; and Daiichi Sankyo to conduct research related to drug targets called ligases that control cancer cell proliferation through protein degradation, as well as a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Autoimmune Disease Chemical Compounds Phosphates Drug Development Ophthalmic Enzymes Rheumatoid Arthritis Asthma Cancer Cell Tyrosine Kinase Lupus Adenosine Protein Kinase Tyrosine Kinase Inhibitors Inflammatory And Autoimmune Diseases Janus Kinase Daiichi Sankyo Discoid Lupus Erythema Muscle Disorders Portola Pharmaceuticals Syk Tyrosine Kinases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.96 |
52 Week Low | 0.712 |
Average Volume | 1,137,622 |
200-Day Moving Average | 1.22 |
50-Day Moving Average | 1.33 |
20-Day Moving Average | 1.43 |
10-Day Moving Average | 1.46 |
Average True Range | 0.11 |
RSI (14) | 46.24 |
ADX | 30.07 |
+DI | 24.30 |
-DI | 19.38 |
Chandelier Exit (Long, 3 ATRs) | 1.41 |
Chandelier Exit (Short, 3 ATRs) | 1.43 |
Upper Bollinger Bands | 1.68 |
Lower Bollinger Band | 1.17 |
Percent B (%b) | 0.33 |
BandWidth | 36.30 |
MACD Line | 0.03 |
MACD Signal Line | 0.05 |
MACD Histogram | -0.0235 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.42 | ||||
Resistance 3 (R3) | 1.41 | 1.39 | 1.40 | ||
Resistance 2 (R2) | 1.39 | 1.37 | 1.39 | 1.40 | |
Resistance 1 (R1) | 1.36 | 1.36 | 1.35 | 1.37 | 1.39 |
Pivot Point | 1.34 | 1.34 | 1.33 | 1.34 | 1.34 |
Support 1 (S1) | 1.31 | 1.32 | 1.30 | 1.32 | 1.29 |
Support 2 (S2) | 1.29 | 1.31 | 1.29 | 1.28 | |
Support 3 (S3) | 1.26 | 1.29 | 1.28 | ||
Support 4 (S4) | 1.27 |